Copyright: ©Author(s) 2026.
Figure 1 Main findings of the study.
MASLD: Metabolic dysfunction-associated steatotic liver disease; T2DM: Type 2 diabetes mellitus.
- Citation: Ruiz-Margáin A, Fierro-Angulo OM, González-Regueiro JA, Hernández-Jiménez SC, García-Ulloa AC, Landa-Anell V, Bril F, Roman-Calleja BM, Romo-Arellano R, Pereira-García A, Chalasani N, Macías-Rodríguez RU. Prevalence and risk factors for metabolic dysfunction-associated steatotic liver disease and fibrosis in recently diagnosed type 2 diabetes. World J Hepatol 2026; 18(8): 123278
- URL: https://www.wjgnet.com/1948-5182/full/v18/i8/123278.htm
- DOI: https://dx.doi.org/10.4254/wjh.123278